Avaleht › Suur depressiivne häire › Ohio
Suur depressiivne häire kliinilised uuringud osariigis Ohio
29 uuringut haiguse Suur depressiivne häire jaoks otsivad osalejaid osariigis Ohio.
Linnad osariigis Ohio
Ametlik uuringutekst (inglise keeles)
A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder
- Patient Priority Clinical Sites LLC, Cincinnati
VärbamineFaas 3
Vanused 18–74 · Kõik sood · Uuendatud 1. okt 2026 · NCT07573176Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms
- Patient Priority Clinical Sites LLC, Cincinnati
- The Ohio State University, Columbus
VärbamineFaas 3
Vanused 18–74 · Kõik sood · Uuendatud 25. sept 2026 · NCT06559306Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
- Quest Therapeutics of Avon Lake, Avon Lake
- University of Cincinnati Medical Center, Cincinnati
- The Ohio State University, Columbus
VärbamineFaas 3
Vanused 18–65 · Kõik sood · Uuendatud 25. sept 2026 · NCT05850689A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder
- University of Cincinnati, Cincinnati
VärbamineFaas 3
Vanused 12–17 · Kõik sood · Uuendatud 25. sept 2026 · NCT07227454Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder
- Vanda Investigational Site, Cincinnati
VärbamineFaas 3
Vanused 18–65 · Kõik sood · Uuendatud 24. sept 2026 · NCT06830044A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
- Neurocrine Clinical Site, Independence
VärbamineFaas 4
Vanused 18 ja vanemad · Kõik sood · Uuendatud 18. sept 2026 · NCT07105111A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)
- Seaport Investigator Site, Independence
- Seaport Investigator Site, North Canton
VärbamineFaas 2
Vanused 18–65 · Kõik sood · Uuendatud 14. sept 2026 · NCT07065240ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response
- Neuro-Behavioral Clinical Research, North Canton
VärbamineFaas 2
Vanused 18–65 · Kõik sood · Uuendatud 14. sept 2026 · NCT07284667A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)
- Insight Clinical Trials, Independence
VärbamineFaas 3
Vanused 18–74 · Kõik sood · Uuendatud 8. sept 2026 · NCT07076407A Study to Evaluate the Effectiveness of DT-101 as an Adjunctive Treatment in Patients With Depression
- Draig Clinical Site, Columbus
VärbamineFaas 2
Vanused 18–75 · Kõik sood · Uuendatud 2. sept 2026 · NCT07610473Treatment ResistAnt Depression Subcallosal CingulatE Network DBS (TRANSCEND)
- The Cleveland Clinic Foundation, Cleveland
- The Ohio State University, Columbus
Värbamine
Vanused 22–70 · Kõik sood · Uuendatud 28. aug 2026 · NCT06423430Positive Processes and Transition to Health (PATH)
- Case Western Reserve University, Cleveland
Värbamine
Vanused 18–65 · Kõik sood · Uuendatud 19. aug 2026 · NCT06093906NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
- Neurocrine Clinical Site, Mason
VärbamineFaas 3
Vanused 18 ja vanemad · Kõik sood · Uuendatud 11. aug 2026 · NCT06911112A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)
- Cleveland Clinic, Cleveland
VärbamineFaas 3
Vanused 18–74 · Kõik sood · Uuendatud 10. aug 2026 · NCT07592689Modulating Spinal Interoceptive Pathways to Evaluate Their Role and Therapeutic Potential in MDD Symptomatic Domains
- Lindner Center of Hope, Mason
VärbamineFaas 1/2
Vanused 18–60 · Kõik sood · Uuendatud 3. aug 2026 · NCT06795451A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder
- Neuro-Behavioral Clinical Research, North Canton
VärbamineFaas 3
Vanused 18–74 · Kõik sood · Uuendatud 3. aug 2026 · NCT06775379Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder
- Insight Clinical Trials LLC, Independence
VärbamineFaas 2
Vanused 18–64 · Kõik sood · Uuendatud 3. aug 2026 · NCT06547489A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder
- Insight Clinical Trials LLC, Independence
VärbamineFaas 2
Vanused 18–64 · Kõik sood · Uuendatud 27. juuli 2026 · NCT07115329Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
- Neurocrine Clinical Site, Avon Lake
VärbamineFaas 3
Vanused 18 ja vanemad · Kõik sood · Uuendatud 24. juuli 2026 · NCT06966401Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol
- Clinical Research Site, Cincinnati
- Clinical Research Site, Cincinnati
VärbamineFaas 3
Vanused 18–65 · Kõik sood · Uuendatud 24. juuli 2026 · NCT07484217A Mechanistic Study to Assess a Single Dose of CYB003 in Participants With Depression and Anxiety
- The Ohio State University Department of Psychiatry, Columbus
VärbamineFaas 2
Vanused 21–65 · Kõik sood · Uuendatud 23. juuli 2026 · NCT06820723A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder
- Quest Therapeutics of Avon /ID# 277550, Avon Lake
- OSU Psychiatry Department /ID# 277529, Columbus
VärbamineFaas 2
Vanused 18–65 · Kõik sood · Uuendatud 15. juuni 2026 · NCT07276997A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA)
- The Ohio State University, Columbus
- Neuro Behavioral Clinical Research, Inc., North Canton
VärbamineFaas 2
Vanused 18–65 · Kõik sood · Uuendatud 11. mai 2026 · NCT06524830Improving Outcomes in Adolescent Inpatient Depression With Deep Transcranial Magnetic Stimulation
- Cincinnati Childrens Hospital Medical Center, Cincinnati
Värbamine
Vanused 14–18 · Kõik sood · Uuendatud 11. veebr 2026 · NCT07217444Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY)
- Autobahn Site #109, Beachwood
VärbamineFaas 2
Vanused 18–65 · Kõik sood · Uuendatud 20. jaan 2026 · NCT06633016Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
- Neurocrine Clinical Site, Avon Lake
VärbamineFaas 3
Vanused 18 ja vanemad · Kõik sood · Uuendatud 29. okt 2025 · NCT06786624Mechanisms of Rumination Change in Adolescent Depression
- Nationwide Children's Hospital, Columbus
- The Ohio State University, Columbus
Värbamine
Vanused 14–17 · Kõik sood · Uuendatud 11. aug 2025 · NCT03859297Study of ALTO-300 in MDD
- Site 202, Cincinnati
VärbamineFaas 2
Vanused 18–70 · Kõik sood · Uuendatud 24. juuli 2025 · NCT05922878A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms
- Clinical Research Site, Cincinnati
VärbamineFaas 4
Vanused 18–65 · Kõik sood · Uuendatud 23. jaan 2025 · NCT06223880Allikas ClinicalTrials.gov, andmed saadud 5. okt 2026. Igal uuringul on oma osalemiskõlblikkuse tingimused; uuringumeeskond otsustab, kes saab osaleda.